ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
… in 2019. QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the … N.V. entered into a research collaboration to apply Axiomer ® to fibrosis targets selected by Galapagos. Positive … trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, CEO of ProQR. “We are …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
… not proceed, our primary focus at ProQR remains on our Axiomer ® RNA editing platform,” said Daniel A. de Boer, … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called … in mind. Learn more about ProQR at www.proqr.com . About Axiomer® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … please contact your Chardan representative. About Axiomer ® ProQR is pioneering a next-generation RNA base …
Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le